Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group

Purpose Because we had observed in the synovial sarcoma subgroup of a broad phase III advanced soft tissue sarcoma study a significantly greater objective regression rate from ifosfamide+doxorubicin (88%) than from doxorubicin alone (20%) (P = 0.02), the Eastern Cooperative Oncology Group (ECOG) dec...

Descripción completa

Detalles Bibliográficos
Autores principales: Edmonson, John H., Ryan, Louise M., Falkson, Carla I., Hicks, David G., Blum, Ronald H.
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2003
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395511/
https://www.ncbi.nlm.nih.gov/pubmed/18521363
http://dx.doi.org/10.1080/1357714031000114156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2395511/
https://www.ncbi.nlm.nih.gov/pubmed/18521363
http://dx.doi.org/10.1080/1357714031000114156

Ejemplares similares